Recon: Blueprint's $250M preclinical buy; WHO, CDC, Biden react to Omicron variant
ReconKari Oakes
APIsBiologicsBiotechnologyCombination ProductsDiagnosticsGlobalMedical DevicesPharmaceuticalsReconKari OakesAPIsBiologicsBiotechnologyCombination ProductsDiagnosticsGlobalMedical DevicesPharmaceuticals